ALNY logo

Alnylam Pharmaceuticals (ALNY) Revenue

Annual Revenue

$2.25 B
+$419.95 M+22.97%

December 31, 2024


Summary


Performance

ALNY Revenue Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherALNYprofitabilitymetrics:

Quarterly Revenue

$593.17 M
+$92.25 M+18.42%

December 31, 2024


Summary


Performance

ALNY Quarterly Revenue Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

Related metrics

TTM Revenue

$2.25 B
+$153.45 M+7.33%

December 31, 2024


Summary


Performance

ALNY TTM Revenue Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherALNYprofitabilitymetrics:

ALNY Revenue Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+23.0%+34.9%+23.0%
3 y3 years+166.3%+34.9%+23.0%
5 y5 years+923.1%+34.9%+23.0%

ALNY Revenue Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+166.3%-21.0%+178.1%-4.1%+166.3%
5 y5-yearat high+923.1%-21.0%+727.5%-4.1%+923.1%
alltimeall timeat high>+9999.0%-21.0%>+9999.0%-4.1%>+9999.0%

Alnylam Pharmaceuticals Revenue History

DateAnnualQuarterlyTTM
Dec 2024
$2.25 B(+23.0%)
$593.17 M(+18.4%)
$2.25 B(+7.3%)
Sep 2024
-
$500.92 M(-24.1%)
$2.09 B(-10.6%)
Jun 2024
-
$659.83 M(+33.5%)
$2.34 B(+17.0%)
Mar 2024
-
$494.33 M(+12.4%)
$2.00 B(+9.6%)
Dec 2023
$1.83 B(+76.2%)
$439.72 M(-41.4%)
$1.83 B(+6.1%)
Sep 2023
-
$750.53 M(+135.5%)
$1.72 B(+39.3%)
Jun 2023
-
$318.75 M(-0.2%)
$1.24 B(+8.2%)
Mar 2023
-
$319.29 M(-4.7%)
$1.14 B(+10.2%)
Dec 2022
$1.04 B(+22.9%)
$335.04 M(+26.8%)
$1.04 B(+8.0%)
Sep 2022
-
$264.31 M(+17.6%)
$960.92 M(+8.7%)
Jun 2022
-
$224.82 M(+5.4%)
$884.25 M(+0.5%)
Mar 2022
-
$213.26 M(-17.5%)
$879.98 M(+4.2%)
Dec 2021
$844.29 M(+71.3%)
$258.54 M(+37.8%)
$844.29 M(+12.7%)
Sep 2021
-
$187.63 M(-14.9%)
$749.31 M(+9.0%)
Jun 2021
-
$220.55 M(+24.2%)
$687.53 M(+20.4%)
Mar 2021
-
$177.57 M(+8.6%)
$570.94 M(+15.8%)
Dec 2020
$492.85 M(+124.3%)
$163.56 M(+30.0%)
$492.85 M(+22.9%)
Sep 2020
-
$125.85 M(+21.1%)
$400.97 M(+16.2%)
Jun 2020
-
$103.96 M(+4.5%)
$345.18 M(+20.7%)
Mar 2020
-
$99.48 M(+38.8%)
$285.93 M(+30.1%)
Dec 2019
$219.75 M(+193.4%)
$71.68 M(+2.3%)
$219.75 M(+30.0%)
Sep 2019
-
$70.06 M(+56.7%)
$169.10 M(+67.2%)
Jun 2019
-
$44.71 M(+34.3%)
$101.11 M(+17.2%)
Mar 2019
-
$33.29 M(+58.3%)
$86.30 M(+15.2%)
Dec 2018
$74.91 M(-16.7%)
$21.03 M(+916.6%)
$74.91 M(-18.4%)
Sep 2018
-
$2.07 M(-93.1%)
$91.80 M(-14.1%)
Jun 2018
-
$29.91 M(+36.6%)
$106.83 M(+15.1%)
Mar 2018
-
$21.90 M(-42.3%)
$92.85 M(+3.3%)
Dec 2017
$89.91 M(+90.7%)
$37.92 M(+121.8%)
$89.91 M(+29.5%)
Sep 2017
-
$17.10 M(+7.3%)
$69.44 M(+5.2%)
Jun 2017
-
$15.93 M(-16.0%)
$66.00 M(+12.3%)
Mar 2017
-
$18.96 M(+8.6%)
$58.77 M(+24.6%)
Dec 2016
$47.16 M(+14.8%)
$17.45 M(+27.9%)
$47.16 M(+26.6%)
Sep 2016
-
$13.65 M(+56.7%)
$37.26 M(+24.5%)
Jun 2016
-
$8.71 M(+18.6%)
$29.93 M(+0.1%)
Mar 2016
-
$7.34 M(-2.7%)
$29.91 M(-27.2%)
Dec 2015
$41.10 M(-18.7%)
$7.55 M(+19.4%)
$41.10 M(-28.6%)
Sep 2015
-
$6.32 M(-27.2%)
$57.56 M(-7.5%)
Jun 2015
-
$8.69 M(-53.1%)
$62.21 M(+2.3%)
Mar 2015
-
$18.54 M(-22.8%)
$60.82 M(+20.3%)
Dec 2014
$50.56 M
$24.02 M(+118.9%)
$50.56 M(+35.2%)
Sep 2014
-
$10.97 M(+50.4%)
$37.39 M(+5.6%)
Jun 2014
-
$7.29 M(-11.8%)
$35.41 M(-3.8%)
DateAnnualQuarterlyTTM
Mar 2014
-
$8.28 M(-23.7%)
$36.80 M(-22.0%)
Dec 2013
$47.17 M(-29.3%)
$10.85 M(+20.6%)
$47.17 M(+5.2%)
Sep 2013
-
$8.99 M(+3.5%)
$44.81 M(-14.8%)
Jun 2013
-
$8.69 M(-53.4%)
$52.58 M(-18.8%)
Mar 2013
-
$18.64 M(+119.4%)
$64.78 M(-2.9%)
Dec 2012
$66.72 M(-19.4%)
$8.49 M(-49.3%)
$66.72 M(-15.2%)
Sep 2012
-
$16.76 M(-19.8%)
$78.69 M(-4.9%)
Jun 2012
-
$20.88 M(+1.4%)
$82.72 M(+0.3%)
Mar 2012
-
$20.59 M(+0.6%)
$82.45 M(-0.4%)
Dec 2011
$82.76 M(-17.3%)
$20.45 M(-1.6%)
$82.76 M(-0.9%)
Sep 2011
-
$20.79 M(+0.9%)
$83.49 M(-7.6%)
Jun 2011
-
$20.61 M(-1.4%)
$90.37 M(-6.2%)
Mar 2011
-
$20.90 M(-1.4%)
$96.37 M(-3.7%)
Dec 2010
$100.04 M(-0.5%)
$21.19 M(-23.4%)
$100.04 M(-5.2%)
Sep 2010
-
$27.67 M(+3.9%)
$105.47 M(+3.4%)
Jun 2010
-
$26.62 M(+8.4%)
$102.06 M(+2.0%)
Mar 2010
-
$24.56 M(-7.7%)
$100.04 M(-0.5%)
Dec 2009
$100.53 M(+4.5%)
$26.63 M(+9.8%)
$100.53 M(+2.3%)
Sep 2009
-
$24.25 M(-1.4%)
$98.31 M(-1.5%)
Jun 2009
-
$24.60 M(-1.8%)
$99.80 M(+0.8%)
Mar 2009
-
$25.06 M(+2.7%)
$99.03 M(+3.0%)
Dec 2008
$96.16 M(+88.9%)
$24.40 M(-5.2%)
$96.16 M(+6.9%)
Sep 2008
-
$25.73 M(+8.0%)
$89.99 M(+11.7%)
Jun 2008
-
$23.83 M(+7.4%)
$80.57 M(+22.3%)
Mar 2008
-
$22.19 M(+21.7%)
$65.87 M(+29.4%)
Dec 2007
$50.90 M(+89.0%)
$18.23 M(+11.7%)
$50.90 M(+28.4%)
Sep 2007
-
$16.32 M(+78.6%)
$39.65 M(+25.7%)
Jun 2007
-
$9.13 M(+26.5%)
$31.54 M(+10.9%)
Mar 2007
-
$7.22 M(+3.4%)
$28.43 M(+5.6%)
Dec 2006
$26.93 M(+371.1%)
$6.98 M(-15.0%)
$26.93 M(+25.2%)
Sep 2006
-
$8.21 M(+36.4%)
$21.50 M(+46.2%)
Jun 2006
-
$6.02 M(+5.3%)
$14.70 M(+50.2%)
Mar 2006
-
$5.72 M(+268.4%)
$9.79 M(+71.3%)
Dec 2005
$5.72 M(+33.6%)
$1.55 M(+9.8%)
$5.72 M(-16.1%)
Sep 2005
-
$1.41 M(+27.5%)
$6.81 M(+0.7%)
Jun 2005
-
$1.11 M(-32.6%)
$6.76 M(+16.9%)
Mar 2005
-
$1.64 M(-37.9%)
$5.79 M(+35.3%)
Dec 2004
$4.28 M(+2330.7%)
$2.65 M(+93.6%)
$4.28 M(+155.3%)
Sep 2004
-
$1.37 M(+943.5%)
$1.68 M(+374.8%)
Jun 2004
-
$131.00 K(-2.2%)
$353.00 K(+59.0%)
Mar 2004
-
$134.00 K(+204.5%)
$222.00 K(+152.3%)
Dec 2003
$176.00 K
$44.00 K(0.0%)
$88.00 K(+100.0%)
Sep 2003
-
$44.00 K
$44.00 K

FAQ

  • What is Alnylam Pharmaceuticals annual revenue?
  • What is the all time high annual revenue for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals annual revenue year-on-year change?
  • What is Alnylam Pharmaceuticals quarterly revenue?
  • What is the all time high quarterly revenue for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals quarterly revenue year-on-year change?
  • What is Alnylam Pharmaceuticals TTM revenue?
  • What is the all time high TTM revenue for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals TTM revenue year-on-year change?

What is Alnylam Pharmaceuticals annual revenue?

The current annual revenue of ALNY is $2.25 B

What is the all time high annual revenue for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high annual revenue is $2.25 B

What is Alnylam Pharmaceuticals annual revenue year-on-year change?

Over the past year, ALNY annual revenue has changed by +$419.95 M (+22.97%)

What is Alnylam Pharmaceuticals quarterly revenue?

The current quarterly revenue of ALNY is $593.17 M

What is the all time high quarterly revenue for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high quarterly revenue is $750.53 M

What is Alnylam Pharmaceuticals quarterly revenue year-on-year change?

Over the past year, ALNY quarterly revenue has changed by +$153.45 M (+34.90%)

What is Alnylam Pharmaceuticals TTM revenue?

The current TTM revenue of ALNY is $2.25 B

What is the all time high TTM revenue for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high TTM revenue is $2.34 B

What is Alnylam Pharmaceuticals TTM revenue year-on-year change?

Over the past year, ALNY TTM revenue has changed by +$419.95 M (+22.97%)